openPR Logo
Press release

Insomnia Market Research Report 2026

04-12-2017 07:34 PM CET | Health & Medicine

Press release from: Transparency Market Research – Pharmaceutical

Global Insomnia Market: Brief Account

The world insomnia market is envisaged to recoup promisingly from its drowsy growth in the past with a number of worthwhile and well-timed opportunities to take advantage of. Insomnia drugs could find an application in the treatment of Parkinson and Alzheimer’s disease as sedatives. The younger population can increase the global demand as intensively as the geriatric group with rising stress levels and persisting diseases such as cancer at the forefront. The launch of new products such as E-2006 by Eisai Co. Ltd. and Belsomra by Merck & Co. Inc. is forecasted to stimulate the market growth handsomely.

Download The Full Brouchre of Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20246

The global insomnia market could be segmented according to over-the-counter (OTC) treatment, non-pharmacological treatments, and pharmacological treatments, where each category is evaluated to contribute their part toward the global growth.

The researchers who have authored this report prioritize painstaking primary and secondary research to compile statistical data and other analytics of the global insomnia market. Players in the market can gain a decisive insight into the guidelines required to extend their portfolio in the right direction and achieve a tangible success in the market.

Global Insomnia Market: Key Trends

With the two premier categorizations of the worldwide insomnia market into play, viz. non-pharmacological treatments and pharmacological treatments, manufacturers can expect lucrative prospects from both the segments. The cognitive behavioral therapy for insomnia (CBTI) listed under non-pharmacological treatments extends the ability of physicians to heal patients or understand their health issues in a comprehensive manner. Such treatments including hypnotherapy can be employed by doctors to take multiple approaches during the treatment of their patients. There are other treatments such as aroma music, bright light, biofeedback, acupuncture, and yoga therapies which could contribute to the growth of the non-pharmacological treatments market.

Likewise, pharmacological treatments are prognosticated to lay a strong platform for the global insomnia market to find more growth prospects on the back of key segments such as OTC sleep aids and prescription sleep aids.

The international insomnia market could go through a downtime period due to inferior diagnosis rate, below par patient compliance, patent erosion, and ascendancy of generic products. Howbeit, the surging incidences of insomnia and unfulfilled medical needs, for instance, the inefficiency of central nervous system (CNS) drugs, are foreseen to compensate for the probable decline in growth.

Global Insomnia Market: Geographical Study

For the most part of the share in world insomnia market, the Americas including North America are foretold to showcase extensive dominance while offering some groundbreaking opportunities for global players. In the U.S., the OTC treatment market is anticipated to register a higher CAGR to address its growth in the insomnia pharmacological treatment sector. The OTC sleep aids market can be classified into valerian roots, melatonin, and antihistamines. An increasing number of patients are convinced to adopt OTC sleep aids because of the infamous side effects caused by prescription drugs and low prices and easy availability of OTC treatments. The U.S. insomnia market is predicted to gain support from the rising consumption of valerian roots and melatonin, owing to their crucial advantages such as decreased stress levels and less side effects.

Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/insomnia-market.html

The Americas could be followed by Europe, the Middle East, and Africa on account of the augmenting interest in spreading health awareness through various programs and inflating geriatric population. The insomnia market in Asia Pacific is also looked upon as a decent opportunity for vendors to capitalize on with the elevating disposable income and upsurge in the occurrence of chronic diseases.

Global Insomnia Market: Top Companies

Some of the prominent companies functioning in the international insomnia market are Purdue Pharma L.P., Pernix Therapeutics, Takeda Pharmaceutical Company Ltd., Sanofi, Pfizer, Inc., Meda Consumer Healthcare Inc., Merck & Co. Inc., and Eisai, Co. Ltd.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insomnia Market Research Report 2026 here

News-ID: 500706 • Views:

More Releases from Transparency Market Research – Pharmaceutical

Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025
Plasma Protease C1-inhibitor Treatment Market Estimated to Flourish by 2025
A fresh market intelligence study by Transparency Market Research (TMR) states that the business landscape of the global plasma protease c1-inhibitor treatment market is consolidated with intense competitive rivalry among leading players. TMR detects Shire plc led the global plasma protease C1-inhibitor treatment market in 2016. Key factors that account for its dominance are expanded product portfolio, acquisitions, and widespread market presence. Pharming Group N.V., CSL Limited, and Sanquin are
Narcolepsy Market - Global Industry Trends and Forecast - 2019
Narcolepsy Market - Global Industry Trends and Forecast - 2019
Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is
Diabetic Macular Edema Market - Key Growth Factors and Forecast 2019
Diabetic Macular Edema Market - Key Growth Factors and Forecast 2019
Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). Obtain Report Details @ http://www.transparencymarketresearch.com/diabetic-macular-edema-market.html Diabetic macular edema is the major reason for loss of vision in patients
Primary Systemic Amyloidosis Market- Get Facts About Business Strategies and Financial Status over Forecast Period 2020.
Primary Systemic Amyloidosis Market- Get Facts About Business Strategies and Fin …
Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs

All 5 Releases


More Releases for OTC

Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to
Investigation for Long-Term Investors in shares of Volkswagen AG (OTC: VWAGY / O …
An investigation on behalf of current long-term investors in shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) was announced over potential breaches of fiduciary duties by certain officers and directors at Volkswagen AG. Investors who purchased shares of Volkswagen AG (OTC: VWAGY / OTC: VLKAF / OTC: VWAPY) and currently hold any of those Volkswagen AG shares have certain options and should contact the Shareholders Foundation at
OTC: VWAGY / OTC: VLKAF / OTC: VWAPY Shareholder Notice: Update in Lawsuit again …
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Volkswagen AG (OTC: VWAGY) (OTC: VWAPY) shares. Investors, who purchased shares of Volkswagen AG (OTC: VWAGY) (OTC: VLKAF) (OTC: VWAPY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On September 25, 2015, a lawsuit was filed against Volkswagen AG (alleged securities laws violations. The plaintiff claimed that the defendants
OTC Analgesics Market OTC analgesics market is projected to register a steady ex …
About OTC Analgesics Market The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of OTC analgesics is estimated to account for nearly US$ 25,000 Mn revenues by 2022-end. Get Sample copy of this Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=75 The trend of using off-label drugs that are affordable and unapproved, but effective in treating diseases, has been witnessing an upsurge over the past few years.
03-14-2018 | Health & Medicine
Fact.MR
OTC Analgesics Market Report 2017-22: Pharmacy to Remain the Most Lucrative OTC …
A fresh study, covering “OTC Analgesics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2022” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends to make
The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects
ReportsWeb.com has announced the addition of the “Global OTC Drugs Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. GBI Research's latest report, "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current